Larazotide occupies an unusual position among research peptides. It has a clearly described mechanism, it reached late-stage clinical evaluation in a defined indication, and that evaluation did not succeed. All three facts belong together, and the third is frequently omitted.
This guide covers what larazotide is, how tight junction regulation works, what the clinical programme found, and what any of that means for research use.
What Is Larazotide?
Larazotide, also designated AT-1001, is a synthetic eight-amino-acid peptide described as a tight junction regulator. Its origin is unusual: the sequence derives from work on a cholera toxin, and it shares sequence homology with zonulin, the endogenous protein that regulates intestinal tight junctions.
That homology is the basis of its activity. Larazotide acts at zonulin receptors in the intestinal epithelium, and it is characterised as an antagonist rather than an agonist. It occupies the receptor without producing the downstream signal.
How Does Tight Junction Regulation Work?
Tight junctions are the protein complexes sealing the space between adjacent epithelial cells. They determine how much material crosses an epithelium between cells rather than through them, a route described as the paracellular pathway.
That seal is not fixed. Zonulin signalling triggers reversible disassembly of tight junction complexes, increasing paracellular permeability. This is a normal physiological mechanism, and dysregulation of it is the subject of a large literature on intestinal barrier function.
In coeliac disease specifically, gliadin fragments are described as initiating a cascade that opens tight junctions and increases permeability. Larazotide intervenes upstream of the opening, preventing tight junction disassembly and the associated increase in permeability rather than reversing it afterwards.
The mechanistic logic is preventive rather than corrective, and that shapes how the compound behaves in model systems: it is studied for maintaining a barrier under challenge, not for restoring one already compromised.
What Does the Research Actually Show?
The mechanistic literature and the clinical literature point in different directions, and both should be read.
In model systems, larazotide’s effect on permeability under challenge is reasonably well characterised, and transepithelial electrical resistance and tracer flux measurements in epithelial monolayers are the standard readouts.
The clinical programme is the part usually left out of supplier descriptions. Larazotide advanced to Phase 3 evaluation in coeliac disease under 9 Meters Biopharma. In 2022 the company announced discontinuation of that Phase 3 trial, on the basis that an interim analysis did not support continuation. The compound has not been approved for coeliac disease or any other indication.
That is not a reason to disregard the molecule. A well-characterised receptor antagonist that failed to demonstrate clinical benefit in one indication remains a useful tool for studying the pathway it acts on. It is a reason to be precise: larazotide is a research compound with a negative late-stage clinical result, not an emerging therapy awaiting approval.
How Should the Failed Trial Be Interpreted?
An interim analysis that does not support continuation can mean several things, and the distinction matters to anyone designing work around the compound.
It may indicate insufficient separation from placebo on the chosen endpoint. It may reflect an endpoint that did not capture the mechanism well. It may reflect a population in which the mechanism was not the dominant driver of symptoms. Discontinuation at interim analysis generally reflects a futility assessment rather than a safety signal, though the public record is the authority on any specific programme.
For research purposes the useful reading is that barrier permeability, as modulated by this mechanism, did not translate into the clinical benefit the trial was designed to detect in that population. Whether the mechanism itself is sound and the translation failed, or the mechanism contributes less than hypothesised, is precisely the sort of question a research compound is used to investigate.
How Is It Handled and Stored?
Larazotide is a short synthetic peptide and is handled accordingly: lyophilised material stored at low temperature, protection from repeated freeze-thaw, single-use aliquots after reconstitution.
One property is worth noting for experimental design. The compound was developed for local activity at the intestinal epithelium rather than systemic exposure, and it is described as having limited systemic absorption. Work designed around a systemic exposure model is therefore working against the molecule’s characterised behaviour.
Stability considerations for short peptides apply as usual, and oxidation and deletion-sequence content are the routine concerns. Our overview of quality control framework covers how batch documentation should be structured.
What the Permeability Readouts Measure
Work with larazotide in epithelial systems relies on a small set of standard measurements, and knowing what each captures helps in reading the literature.
Transepithelial electrical resistance measures the electrical resistance across a cell monolayer, which rises as tight junctions seal and falls as they open. It is non-destructive and can be measured repeatedly on the same monolayer, which makes it well suited to time-course work.
Tracer flux assays measure how much of a labelled molecule crosses the monolayer over a defined period. Because tracers of different sizes cross by different routes, the choice of tracer determines what the assay is sensitive to, and results obtained with differently sized tracers are not directly comparable.
The two readouts do not always move together, and a discrepancy between them is informative rather than an error. Resistance is dominated by ion flux through the smallest pathway, while larger tracers report on a different aspect of barrier integrity.
How Do You Know You Are Getting What You Paid For?
For an octapeptide, verification is straightforward in principle and still worth insisting on.
Identity should be confirmed by mass spectrometry against the expected mass for the eight-residue sequence. Purity by HPLC should show the full-length species as the principal peak, with attention to deletion sequences, which are the characteristic impurity of solid-phase synthesis and can be difficult to separate from the target.
Net peptide content and counter-ion should be stated. Trifluoroacetate contributes to gross vial weight without contributing peptide, and for permeability work where concentration-response relationships are the object of measurement, that discrepancy transfers directly into the reported values. Our checklist for assessing a peptide lab sets out the full documentation set.
Who Is Studying It, and For What?
Research interest centres on intestinal barrier function. Beyond coeliac disease, the permeability literature extends into inflammatory bowel disease, environmental enteropathy, and the broader question of whether barrier dysfunction is causal or consequent in a range of conditions.
Larazotide is also used as a tool compound. Where an experiment needs paracellular permeability constrained in order to establish what a permeability increase was contributing, a characterised antagonist is the instrument for doing that.
Barrier and mucosal work overlaps with other peptides in this space, and our overview of KPV covers a different mechanism with an adjacent research audience.
Reading Supplier Descriptions Critically
Descriptions of this compound vary widely in how they characterise its development history, and the variation is informative.
Some describe it as an investigational therapy for coeliac disease without mentioning that the Phase 3 programme was discontinued. Others describe the mechanism accurately and omit the clinical outcome entirely. A smaller number state both, which is the standard a researcher should expect.
The reason this matters beyond accuracy is that the clinical result is genuinely informative for study design. A compound that modulates permeability as characterised, yet did not produce the clinical benefit its trial was designed to detect, poses a specific and interesting question about the relationship between the measurement and the outcome. A description that omits the result also omits the question.
The Bottom Line for Researchers
Larazotide is a well-defined octapeptide zonulin antagonist with a clear mechanism and a documented negative Phase 3 result in coeliac disease. Both halves belong in any accurate description of it. As a tool for interrogating tight junction regulation it remains genuinely useful, and as a candidate therapy it has a public record that supplier copy tends not to mention.
Designing Around a Preventive Mechanism
Because larazotide acts to prevent tight junction disassembly rather than to reverse it, the timing of exposure relative to challenge is the variable that most often determines whether an experiment detects anything.
Applying the compound after a barrier has already been disrupted tests a different hypothesis from applying it before or alongside a challenge, and a null result from the former says little about the latter. Published protocols differ on this point, which is one reason results across studies can appear inconsistent.
Concentration-response characterisation in the specific system is likewise necessary rather than optional. Epithelial models differ in baseline resistance, in junctional protein expression and in how they respond to a given challenge, so an effective concentration established in one line is a starting point for another rather than a specification.
Frequently Asked Questions
What is larazotide?
A synthetic eight-amino-acid peptide, also designated AT-1001, that acts as a tight junction regulator by antagonising zonulin receptors in the intestinal epithelium.
How does larazotide work?
It blocks zonulin receptors, preventing the tight junction disassembly and increase in paracellular permeability that zonulin signalling would otherwise produce. The action is preventive rather than corrective.
Was larazotide approved for coeliac disease?
No. It reached Phase 3 under 9 Meters Biopharma, and in 2022 the company announced discontinuation of that trial after an interim analysis did not support continuation. It has not been approved for any indication.
Does the failed trial mean the mechanism is wrong?
Not necessarily. A futility outcome can reflect the endpoint, the population or the magnitude of the mechanism’s contribution rather than the mechanism being incorrect. Distinguishing those is itself a research question.
What is zonulin?
An endogenous protein that regulates intestinal tight junctions, triggering reversible disassembly and increasing paracellular permeability. Larazotide shares sequence homology with it.
Is larazotide systemically absorbed?
It is described as having limited systemic absorption, having been developed for local activity at the intestinal epithelium. Designs assuming systemic exposure work against its characterised behaviour.
This article is provided for educational and research purposes only. AminoQuest Labs peptides are sold for laboratory research use and are not intended for human consumption or medical use.
